Vantage Investment Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
$5.89M Buy
54,874
+4,335
+9% +$433K 1.24% 39
2018
Q2
$4.31M Buy
50,539
+46,155
+1,053% +$3.79M 1.05% 42
2018
Q1
$339K Buy
4,384
+800
+22% +$64.4K 0.09% 112
2017
Q4
$303K Hold
3,584
0.07% 127
2017
Q3
$307K Hold
3,584
0.08% 116
2017
Q2
$295K Sell
3,584
-465
-11% -$37.9K 0.09% 109
2017
Q1
$341K Sell
4,049
-150
-4% -$12K 0.11% 100
2016
Q4
$309K Hold
4,199
0.13% 101
2016
Q3
$337K Sell
4,199
-216
-5% -$17.3K 0.15% 88
2016
Q2
$346K Sell
4,415
-109
-2% -$8.21K 0.15% 92
2016
Q1
$326K Buy
4,524
+30
+0.7% +$2.27K 0.14% 93
2015
Q4
$379K Buy
4,494
+60
+1% +$4.98K 0.19% 79
2015
Q3
$371K Buy
4,434
+150
+4% +$12.7K 0.21% 79
2015
Q2
$358K Sell
4,284
-2,169
-34% -$165K 0.2% 85
2015
Q1
$469K Buy
6,453
+1,906
+42% +$136K 0.13% 97
2014
Q4
$314K Hold
4,547
0.18% 85
2014
Q3
$295K Hold
4,547
0.18% 83
2014
Q2
$283K Buy
4,547
+100
+2% +$5.97K 0.17% 87
2014
Q1
$262K Sell
4,447
-155
-3% -$8.65K 0.17% 86
2013
Q4
$234K Buy
+4,602
New +$230K 0.16% 97

Other funds holding LLY

Vantage Investment Advisors's LLY Position: Q3 2018 in Review

Vantage Investment Advisors increased its Eli Lilly (LLY) stake by 8.6% in Q3 2018, buying an estimated $433K and bringing the position to 54,874 shares worth $5.89M. The position accounts for 1.24% of the portfolio, ranked #39.

Vantage Investment Advisors first reported a position in LLY in Q4 2013 and has held it in 20 quarters since. 1,431 funds tracked by Wall St. Rank hold LLY as of Q3 2018.

  • Vantage Investment Advisors held 54,874 shares of Eli Lilly worth $5.89M as of Q3 2018.
  • Vantage Investment Advisors bought 4,335 Eli Lilly shares in Q3 2018, an estimated $433K.
  • Eli Lilly made up 1.24% of Vantage Investment Advisors's portfolio in Q3 2018, its #39 holding.
  • Vantage Investment Advisors first reported a position in Eli Lilly in Q4 2013 and has held it in 20 quarters since.
  • 1,431 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.